---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-041043"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2025-08-22T23:59:59+00:00"
generated_at: "2026-05-17T10:34:28.879241+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Salarius-Decoy merger update: legacy holders ~7.6% stake, $6M minimum financing required

## Summary
- Step one: Decoy stockholders receive ~92.4% of Salarius; legacy holders ~7.6% based on exchange ratio.
- Merger closing conditioned on minimum $6.0M Qualified Financing and continued Nasdaq listing.
- Step two requires stockholder approval for Preferred Stock conversion; Nasdaq initial listing must precede.
- Decoy's lead pan-coronavirus prophylactic IND planned H1 2026; funded by Gates Foundation and BARDA.
- Combined company to explore P-PROTACs using Salarius' SP-3164, initial focus on metastatic colorectal cancer.

## SEC filing metadata
- accession: 0001628280-25-041043
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2025-08-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000162828025041043/0001628280-25-041043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000162828025041043/flks-20250822.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-041043
- JSON: https://secwatch.observer/filing/0001628280-25-041043.json
- Plain text: https://secwatch.observer/filing/0001628280-25-041043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.